Contact

All Stories

  1. Nafamostat Mesilate as an Anticoagulation Strategy for Heparin-Induced Thrombocytopenia: A Case Report

    Article • Journal of Blood Medicine, January 2026, Taylor & Francis

    Dr. Cheng Xue

  2. IL‑1 receptor antagonism attenuates renal fibrosis via RNF182‑driven MFN2 destabilization and mitochondrial dysfunction

    Article • Cell Death Discovery, December 2025, Springer Science + Business Media

    Dr. Cheng Xue

  3. Gut–Kidney Axis Disruption by Antibiotics: Dysbiosis, Renal Dysfunction and Biomarker Insights

    Article • Advances in Biomarker Sciences and Technology, December 2025, Elsevier

    Dr. Cheng Xue

  4. Reproductive dysfunction in hemodialysis: endocrine mechanisms, clinical features, and therapeutic approaches

    Article • Renal Failure, October 2025, Taylor & Francis

    Dr. Cheng Xue

  5. Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series

    Article • Journal of Nephrology, October 2025, Springer Science + Business Media

    Dr. Cheng Xue

  6. Unraveling the Genetic Links Between Polycystic Kidney Disease and Hypertension Through ARL13B

    Article • International Journal of Nephrology and Renovascular Disease, October 2025, Taylor & Francis

    Dr. Cheng Xue

  7. The impact of hemodiafiltration with endogenous reinfusion (HFR) on micronutrient status in patients undergoing maintenance hemodialysis: A randomized crossover trial

    Article • Clinical Nutrition, October 2025, Elsevier

    Dr. Cheng Xue

  8. Application of Surface-Enhanced Raman Spectroscopy and Machine Learning Omics Techniques in the Progression Assessment of Autosomal Dominant Polycystic Kidney Disease

    Article • Kidney Diseases, September 2025, Karger Publishers

    Dr. Cheng Xue

  9. Protein lactylation in kidney diseases

    Article • Frontiers in Cell and Developmental Biology, August 2025, Frontiers

    Dr. Cheng Xue

  10. Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence

    Article • Frontiers in Molecular Biosciences, July 2025, Frontiers

    Dr. Cheng Xue

  11. Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis

    Article • Journal of Nephrology, July 2025, Springer Science + Business Media

    Dr. Cheng Xue

  12. The Influence of Different Kidney Replacement Modalities on Health-Related Quality of Life in ESKD Patients

    Article • Kidney360, June 2025, Wolters Kluwer Health

    Dr. Cheng Xue

  13. Alterations of renal polyamine metabolism in mice with folic acid-induced chronic kidney disease

    Article • Biochemistry and Biophysics Reports, June 2025, Elsevier

    Dr. Cheng Xue

  14. Assessment of thiamine status and its association with clinical parameters in patients undergoing maintenance hemodialysis

    Article • Frontiers in Nutrition, May 2025, Frontiers

    Dr. Cheng Xue

  15. Peridialytic Erythropoietin versus Roxadustat in Hemodialysis-dependent CKD Patients

    Article • American Journal of Nephrology, May 2025, Karger Publishers

    Dr. Cheng Xue

  16. Sarcopenia in Peritoneal Dialysis: Prevalence, Pathophysiology, and Management Strategies

    Article • Kidney Medicine, May 2025, Elsevier

    Dr. Cheng Xue

  17. Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition

    Article • Kidney Diseases, March 2025, Karger Publishers

    Dr. Cheng Xue

  18. Antinephrin autoantibodies: rethinking the pathogenesis of minimal change disease

    Article • Renal Failure, December 2024, Taylor & Francis

    Dr. Cheng Xue

  19. Monocyte/macrophage pyroptosis and C5b-9-induced cyst enlargement in Pkd1−/− mice

    Article • Nephrology Dialysis Transplantation, November 2024, Oxford University Press (OUP)

    Dr. Cheng Xue

  20. COVID-19-Associated Immune Thrombocytopenic Purpura in a Hemodialysis Patient

    Article • Journal of Blood Medicine, November 2024, Taylor & Francis

    Dr. Cheng Xue

  21. Integrated mRNA-seq and miRNA-seq analysis reveals key transcription factors of HNF4α and KLF4 in ADPKD

    Article • Biochemical and Biophysical Research Communications, November 2024, Elsevier

    Dr. Cheng Xue

  22. EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease

    Article • Journal of Translational Medicine, October 2024, Springer Science + Business Media

    Dr. Cheng Xue

  23. Prognostic Assessment of Histopathologic Lesions in Patients with Community-Acquired AKI with Biopsy-Proven Acute Tubular Necrosis

    Article • Kidney360, May 2024, Wolters Kluwer Health

    Dr. Cheng Xue

  24. Deciphering interleukin 37's therapeutic potential: insights into alleviating inflammation in autosomal dominant polycystic kidney disease

    Article • Kidney International, May 2024, Elsevier

    Dr. Cheng Xue

  25. Obstructive uropathy complicated by acute aortic dissection

    Article • CEN Case Reports, April 2024, Springer Science + Business Media

    Dr. Cheng Xue

  26. Tislelizumab induced dual organs dysfunction in a patient with advanced esophageal squamous cell carcinoma: a case report

    Article • Frontiers in Oncology, March 2024, Frontiers

    Dr. Cheng Xue

  27. A pilot study of intensive short‐time continuous renal replacement therapy to substitute maintenance hemodialysis during transitional period of COVID‐19

    Article • Therapeutic Apheresis and Dialysis, November 2023, Wiley

    Dr. Cheng Xue

  28. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels

    Article • BMC Nephrology, September 2023, Springer Science + Business Media

    Dr. Cheng Xue

  29. Potential factors associated with a long-term duration of B-cell depletion after using rituximab in patients with nephrotic syndrome

    Article • Pediatric Nephrology, September 2023, Springer Science + Business Media

    Dr. Cheng Xue

  30. Misdiagnosis of renal pelvic unicentric Castleman disease: a case report

    Article • Frontiers in Surgery, August 2023, Frontiers

    Dr. Cheng Xue

  31. Specific Nutritional Strategy Is Needed for Good Nutritional Status in Autosomal Dominant Polycystic Kidney Disease

    Article • Journal of Renal Nutrition, July 2023, Elsevier

    Dr. Cheng Xue

  32. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD

    Article • Clinical Journal of the American Society of Nephrology, May 2023, Wolters Kluwer Health

    Dr. Cheng Xue

  33. Golden mean of serum uric acid level on the risk of kidney function decline

    Article • Clinical and Experimental Nephrology, March 2023, Springer Science + Business Media

    Dr. Cheng Xue

  34. Vascular calcification on the risk of kidney stone: a meta-analysis

    Article • Renal Failure, March 2023, Taylor & Francis

    Dr. Cheng Xue

  35. Automatic Segmentation of Kidney Volume Using Multi-Module Hybrid Based U-Shape in Polycystic Kidney Disease

    Article • IEEE Access, January 2023, Institute of Electrical & Electronics Engineers (IEEE)

    Dr. Cheng Xue

  36. Urine biomarkers can outperform serum biomarkers in certain diseases

    Article • URINE, January 2023, Elsevier

    Dr. Cheng Xue

  37. A Nomogram to Identify Hyperkalemia Risk in Patients with Advanced CKD

    Article • Kidney360, October 2022, Wolters Kluwer Health

    Dr. Cheng Xue

  38. p-Cresyl sulfate predicts clinical outcomes in sustained peritoneal dialysis: a 5-year follow-up cohort study and meta-analysis

    Article • Renal Failure, October 2022, Taylor & Francis

    Dr. Cheng Xue

  39. Susceptibility of renal fibrosis in diabetes: Role of hypoxia inducible factor‐1

    Article • The FASEB Journal, July 2022, Wiley

    Dr. Cheng Xue

  40. Anoctamin 1 Inhibition Suppresses Cystogenesis by Enhancing Ciliogenesis and the Ciliary Dosage of Polycystins

    Article • Frontiers in Bioscience-Landmark, July 2022, IMR Press

    Dr. Cheng Xue

  41. Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease

    Article • Frontiers in Medicine, July 2022, Frontiers

    Dr. Cheng Xue

  42. In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study

    Article • Frontiers in Medicine, June 2022, Frontiers

    Dr. Cheng Xue

  43. Late venous laceration after inappropriate placement of a left internal jugular hemodialysis catheter: a case report

    Article • Journal of International Medical Research, April 2022, SAGE Publications

    Dr. Cheng Xue

  44. A program for early detection and management of chronic kidney disease

    Article • Renal Failure, February 2022, Taylor & Francis

    Dr. Cheng Xue

  45. Prognostic analysis of crescentic glomerulonephritis with acute kidney injury: a single-center cohort with 5-year follow-up

    Article • International Urology and Nephrology, February 2022, Springer Science + Business Media

    Dr. Cheng Xue

  46. Comparison of Outcomes between Percutaneous and Surgical Placement of Peritoneal Dialysis Catheters in Uremic Patients: A Meta-Analysis

    Article • Blood Purification, September 2021, Karger Publishers

    Dr. Cheng Xue

  47. Fibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progression

    Article • Kidney International Reports, May 2021, Elsevier

    Dr. Cheng Xue

  48. The Role of Renal Pathology in the Prognosis and Recovery of Community-Acquired Acute Kidney Injury

    Article • January 2021, Karger Publishers

    Dr. Cheng Xue

  49. Inflammatory cytokine depletion in severe coronavirus disease 2019 infectious pneumonia

    Article • Medicine, December 2020, Wolters Kluwer Health

    Dr. Cheng Xue

  50. Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review

    Article • Renal Failure, November 2020, Taylor & Francis

    Professor Albert Ong, Dr. Cheng Xue

  51. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis

    Article • Clinical Kidney Journal, November 2020, Oxford University Press (OUP)

    Dr. Cheng Xue

  52. Inflammatory cytokines depletion for severe COVID-19 infectious pneumonia: a case report

    Article • June 2020, Research Square

    Dr. Cheng Xue

  53. The fertility willingness and acceptability of preimplantation genetic testing in Chinese patients with autosomal dominant polycystic kidney disease

    Article • BMC Nephrology, April 2020, Springer Science + Business Media

    Dr. Cheng Xue

  54. Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China

    Article • Kidney Diseases, January 2020, Karger Publishers

    Cheng Xue, Dr. Cheng Xue

  55. Effect of Statins on Renal Function and Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

    Article • Kidney Diseases, January 2020, Karger Publishers

    Dr. Cheng Xue

  56. COVID-19 Infection in a Patient with End-Stage Kidney Disease

    Article • January 2020, Karger Publishers

    Dr. Cheng Xue

  57. Nocturnal Hemodialysis Compared with Conventional Dialysis for End-Stage Renal Disease Treatment in Polycystic Kidney Disease Patients

    Article • Blood Purification, November 2019, Karger Publishers

    Dr. Cheng Xue

  58. Treatment Options for Kidney Failure in China: Conservative Management More Than Dialysis?

    Article • Kidney Medicine, November 2019, Elsevier

    Dr. Cheng Xue

  59. New-onset glucose disorders in peritoneal dialysis patients: a meta-analysis and systematic review

    Article • Nephrology Dialysis Transplantation, June 2019, Oxford University Press (OUP)

    Dr. Cheng Xue

  60. Timing of Renal-Replacement Therapy in Acute Kidney Injury and Sepsis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2019, New England Journal of Medicine (NEJM/MMS)

    Dr. Cheng Xue

  61. Is urinary oxalate inversely correlated with glomerular filtration rate in chronic kidney disease?

    Article • Renal Failure, January 2019, Taylor & Francis

    Dr. Cheng Xue

  62. Identification of Key Genes and Candidated Pathways in Human Autosomal Dominant Polycystic Kidney Disease by Bioinformatics Analysis

    Article • Kidney and Blood Pressure Research, January 2019, Karger Publishers

    Dr. Cheng Xue

  63. Clinical Characteristics and Outcomes of Community-Acquired versus Hospital-Acquired Acute Kidney Injury: A Meta-Analysis

    Article • Kidney and Blood Pressure Research, January 2019, Karger Publishers

    Dr. Cheng Xue

  64. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials

    Article • Oncology Research and Treatment, January 2019, Karger Publishers

    Dr. Cheng Xue

  65. Polycystic Kidney Disease and Renal Fibrosis

    Article • January 2019, Springer Science + Business Media

    Dr. Cheng Xue

  66. Changing procedures for resolving medical disputes in China

    Article • Internal Medicine Journal, December 2018, Wiley

    Dr. Cheng Xue

  67. Preimplantation Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease Applied in China

    Article • American Journal of Kidney Diseases, November 2018, Elsevier

    Dr. Cheng Xue

  68. Fibroblast Growth Factor-23 May Follow Cardiovascular Disease Rather than Causing It in Chronic Kidney Disease

    Article • Journal of the American Society of Nephrology, August 2018, American Society of Nephrology

    Cheng Xue, Dr. Cheng Xue

  69. Dialysis modality and mortality in polycystic kidney disease

    Article • Hemodialysis International, May 2018, Wiley

    Dr. Cheng Xue

  70. Saikosaponin-d inhibits proliferation by up-regulating autophagy via the CaMKKβ–AMPK–mTOR pathway in ADPKD cells

    Article • Molecular and Cellular Biochemistry, April 2018, Springer Science + Business Media

    Dr. Cheng Xue

  71. Total kidney volume: the most valuable predictor of autosomal dominant polycystic kidney disease progression

    Article • Kidney International, March 2018, Elsevier

    Dr. Cheng Xue

  72. Comment to: Differences in characteristics and outcomes between community- and hospital-acquired acute kidney injury: A systematic review and meta-analysis. Clinical Nephrology, 2017; 88: 167-182

    Article • Clinical Nephrology, November 2017, Dustri-Verlgag Dr. Karl Feistle

    Dr. Cheng Xue

  73. Amputation of the first metatarsophalangeal joint due to a giant gouty tophi

    Article • Medicine, October 2017, Wolters Kluwer Health

    Dr. Cheng Xue

  74. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial

    Article • BMJ Open, February 2017, BMJ

    Dr. Cheng Xue

  75. Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease

    Article • American Journal of Nephrology, December 2016, Karger Publishers

    Dr. Cheng Xue

  76. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China

    Article • Kidney Diseases, January 2016, Karger Publishers

    Dr. Cheng Xue

  77. Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials

    Article • Oncotarget, December 2015, Impact Journals, LLC

    Dr. Cheng Xue

  78. Relationship of pre-operative serum brain natriuretic peptide with risk of acute kidney injury after cardiac surgery

    Article • Academic Journal of Second Military Medical University, January 2015, China Science Publishing & Media Ltd.

    Dr. Cheng Xue

  79. Effects ofendothelial nitric oxide synthasegene on end stage renal disease progression in autosomal dominant polycystic kidney disease

    Article • Nephrology, September 2014, Wiley

    Dr. Cheng Xue

  80. 4 G/4 G polymorphism ofplasminogen activator inhibitor-1 geneincreases the risk of diabetic nephropathy

    Article • Renal Failure, December 2013, Taylor & Francis

    Dr. Cheng Xue

  81. Apolipoprotein E Gene Variants on the Risk of End Stage Renal Disease

    Article • PLOS One, December 2013, PLOS

    Dr. Cheng Xue

  82. C509T and T869C polymorphisms of transforming growth factor β1 and the risk of IgA nephropathy: a meta-analysis

    Article • Chinese Medical Journal, December 2013, Wolters Kluwer Health

    Dr. Cheng Xue

  83. Chronic kidney disease-mineral and bone disorder and energy metabolism

    Article • Academic Journal of Second Military Medical University, November 2013, China Science Publishing & Media Ltd.

    Dr. Cheng Xue

  84. Secretoglobin 1A member 1 (SCGB1A1) +38A/G polymorphism is associated with asthma risk: A meta-analysis

    Article • Gene, October 2013, Elsevier

    Dr. Cheng Xue

  85. Long-Term Treatment with Mammalian Target of Rapamycin Inhibitor Does Not Benefit Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis

    Article • Nephron Clinical Practice, January 2013, Karger Publishers

    Dr. Cheng Xue

  86. Histone deacetylases and autosomal dominant polycystic kidney disease

    Article • Academic Journal of Second Military Medical University, October 2011, China Science Publishing & Media Ltd.

    Dr. Cheng Xue